Pharmaceutical Contract Manufacturing and Research Services Market By Service Type (Contract Manufacturing Services, Contract Research Services, Contract Development and Manufacturing Services, Contract Packaging), By Application (Small Molecule, Biologics, Biosimilars, Generics, Over-the-Counter Products), By End-User Industry (Pharmaceutical Manufacturers, Biotechnology Companies, Generic Drug Manufacturers, Contract Research Organizations), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Pharmaceutical Contract Manufacturing and Research Services Market was valued at USD 247.7 Billion in 2024-e and will surpass USD 378.1 Billion by 2030; growing at a CAGR of 7.3% during 2025-2030.

The pharmaceutical contract manufacturing and research services market is integral to the pharmaceutical and biotechnology industries, providing a range of outsourcing solutions for drug development, production, and commercialization. Companies in this market offer services such as contract manufacturing, contract research, and contract development and manufacturing services (CDMO), allowing pharmaceutical companies to focus on core competencies while outsourcing specialized processes. These services also cater to the growing demand for biologics, biosimilars, and generics, providing cost-effective and efficient solutions for drug production and research.

Contract Manufacturing Services Segment Is Largest Owing to High Demand for Cost-Effective Production

The contract manufacturing services segment is the largest in the pharmaceutical contract manufacturing and research services market, driven by the increasing demand for outsourced production. Pharmaceutical companies are increasingly outsourcing their manufacturing needs to reduce costs, enhance operational efficiency, and meet stringent regulatory requirements. Contract manufacturers provide specialized expertise in the large-scale production of drugs, including small molecules and biologics, ensuring compliance with international standards. The growing global demand for drugs, especially generics, has further fueled the need for these services.

As pharmaceutical companies focus on core activities such as research and development, contract manufacturing services allow them to expand their production capacity without significant capital investments in facilities. This is particularly true for generic drug manufacturers who rely heavily on outsourced production to meet global demand. By leveraging contract manufacturers' specialized facilities and capabilities, pharmaceutical companies can achieve greater flexibility, speed, and cost efficiency in production.

Biologics Application Is Fastest Growing Due to Rising Demand for Targeted Therapies

The biologics application segment is the fastest-growing subsegment within the pharmaceutical contract manufacturing and research services market. Biologics, which include therapeutic proteins, monoclonal antibodies, and vaccines, are increasingly being developed to target specific diseases, making them essential in the treatment of conditions such as cancer, autoimmune diseases, and genetic disorders. The rise in chronic diseases and the shift towards personalized medicine are key drivers of the biologics market.

The demand for biologics has prompted pharmaceutical companies to seek out contract development and manufacturing organizations (CDMOs) with specialized capabilities in biologics production. This has led to an increase in strategic partnerships between biopharma companies and contract manufacturers, providing the latter with the necessary expertise and infrastructure to handle the complex production processes involved in biologics manufacturing. As biologics continue to dominate the pharmaceutical pipeline, the demand for contract services in this area is expected to grow rapidly.

Pharmaceutical Manufacturers End-User Industry Leads Owing to Outsourcing Trends

The pharmaceutical manufacturers end-user industry leads the market, as pharmaceutical companies increasingly rely on contract manufacturing and research services to meet the demands of drug production and development. Outsourcing allows pharmaceutical manufacturers to focus on drug discovery, regulatory affairs, and marketing, while leveraging specialized contract research organizations (CROs) and CDMOs to handle production and clinical trials.

Pharmaceutical manufacturers are seeking cost-effective ways to scale up production, particularly for generics and biosimilars. By outsourcing to contract manufacturers, companies can avoid the capital expenditures associated with maintaining large-scale production facilities. This also enables them to meet stringent global regulatory standards and reduce time-to-market for new drugs, especially in a competitive landscape where speed and cost efficiency are crucial for success.

North America Region Is Largest Owing to Established Pharmaceutical Industry

North America is the largest region in the pharmaceutical contract manufacturing and research services market, largely due to the well-established pharmaceutical industry in the United States and Canada. The region is home to some of the world’s largest pharmaceutical companies, many of which rely heavily on outsourcing to CDMOs and contract research organizations (CROs) for drug development and production. North America’s robust healthcare infrastructure, advanced technology, and regulatory frameworks provide an ideal environment for the growth of the pharmaceutical contract manufacturing market.

The demand for outsourced services in North America is driven by the increasing complexity of drug manufacturing, particularly in biologics and biosimilars, and the need for cost-effective production solutions. Additionally, North American pharmaceutical companies are expanding their global reach and outsourcing production to meet growing international demand. The region’s dominance is expected to continue as pharmaceutical companies continue to embrace outsourcing as a strategic approach to improve efficiency and reduce costs.

Leading Companies and Competitive Landscape

The pharmaceutical contract manufacturing and research services market is highly competitive, with several global players providing a wide range of services across different drug types and stages of development. Leading companies in the market include Lonza Group, Catalent, Inc., WuXi AppTec, Patheon (Thermo Fisher Scientific), and Boehringer Ingelheim. These companies are well-positioned to capitalize on the growing demand for biologics, biosimilars, and generics, with strong capabilities in drug development, manufacturing, and commercialization.

The competitive landscape is characterized by strategic partnerships, acquisitions, and investments in advanced manufacturing technologies. Companies are focusing on expanding their service offerings to include biologics and biosimilars production, as well as enhancing their global manufacturing capabilities to cater to the increasing demand for outsourced services. The market is also witnessing the emergence of new players, particularly in emerging markets, as pharmaceutical companies seek to diversify their outsourcing partners and minimize production costs.

Recent Developments:

• Lonza Group and Moderna have extended their partnership for mRNA vaccine production, increasing capacity to meet global demands.
• WuXi AppTec acquired XenoBiotic Laboratories to expand its global footprint and improve its offering of comprehensive preclinical and clinical services to the pharmaceutical industry.
• Thermo Fisher Scientific announced the opening of a state-of-the-art drug manufacturing facility in the United States to support the growing demand for biologics and small molecule production.
• Boehringer Ingelheim has invested $200 million to expand its biologics manufacturing facility in Germany, enhancing production capacity for therapeutic protein production.
• Piramal Pharma Solutions announced a partnership with several biotech companies to provide end-to-end services from drug development to commercialization for biosimilars.

List of Leading Companies:

• Lonza Group
• Catalent, Inc.
• WuXi AppTec
• Samsung Biologics
• Boehringer Ingelheim
• Recipharm AB
• Evonik Industries
• Charles River Laboratories
• Siegfried Holding AG
• Piramal Pharma Solutions
• Jubilant Life Sciences
• Aenova Group
• CordenPharma
• Patheon (Thermo Fisher Scientific)
• Kindeva Drug Delivery

Report Scope: